Posted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines Prices Review Board’s regulatory changes which are set to come into effect on July 1.
The regulatory changes will have significant unintended consequences on patient access to the newest medicines and treatments, while also diverting R&D and investment away from Canada’s life sciences sector.
